← Research library

Viral load and resistance markers in the 352-person zidovudine trial

Observational study · 1996

What was studied
The same 352 zidovudine-treated participants enrolled in the 1995 placebo-controlled trial.
Main finding
Progression to AIDS-related complex, AIDS or death · Across both randomized trial strata, the reanalysis reported a relative hazard of 3.0 favoring thymopentin (p=0.015).

Reported findings and study design

Reported findings

Post hoc analysis of baseline CD4 count, viral load, zidovudine resistance at codon 215 and immune-complex-dissociated p24. The parent trial gave 50 mg thymopentin or placebo subcutaneously three times weekly for up to 48 weeks. Most markers were assayed in stored samples after trial completion.

Population or model The same 352 zidovudine-treated participants enrolled in the 1995 placebo-controlled trial.

Dose, route and schedule

Post hoc analysis of baseline CD4 count, viral load, zidovudine resistance at codon 215 and immune-complex-dissociated p24. The parent trial gave 50 mg thymopentin or placebo subcutaneously three times weekly for up to 48 weeks. Most markers were assayed in stored samples after trial completion.

Protocol source ↗ · Original indexed abstract of the retrospective analysis.

Results · Original indexed abstract of the retrospective analysis.
MeasureResultComparison, timing and statistics
Progression to AIDS-related complex, AIDS or deathAcross both randomized trial strata, the reanalysis reported a relative hazard of 3.0 favoring thymopentin (p=0.015).
Baseline factors associated with progressionCodon 215 mutation, viral load ≥20,000 RNA copies/mL and CD4 below 350 cells/µL were associated with progression. Baseline p24 ≥30 pg/mL was inconclusive (p=0.52).

The treatment analyses were retrospective and used the original randomized cohort. Biomarker subgroup results require independent confirmation. The trial predates current combination HIV therapy.

Source for these results ↗ · Reviewed 2026-11-14

Study limitations and source details

Study limitations

  • The treatment analyses were retrospective and used the original randomized cohort. Biomarker subgroup results require independent confirmation. The trial predates current combination HIV therapy.

Related publications may describe some of the same participants or experiments.

Source details

Original indexed abstract of the retrospective analysis.

Sources checked

Added to the library

Citation

Uncontrolled human reportEnglish abstract

T. C. Merigan, R. L. Hirsch, A. C. Fisher, L. A. Meyerson, G. Goldstein, M. A. Winters. Viral load and resistance markers in the 352-person zidovudine trial AIDS 10(2), 159–165

Study source ↗ · DOI 10.1097/00002030-199602000-00005 · Bibliography entry · Link to this summary

Related compounds

Editorial policy and evidence standards